Major Estimate Revision • Jun 17
Consensus revenue estimates decrease by 13%, EPS upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from CN¥9.56b to CN¥8.35b. EPS estimate increased from CN¥0.45 to CN¥0.51 per share. Net income forecast to shrink 12% next year vs 23% growth forecast for Pharmaceuticals industry in China . Consensus price target up from CN¥7.50 to CN¥8.00. Share price was steady at CN¥9.65 over the past week. New Risk • Apr 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Apr 08
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: CN¥0.46 (down from CN¥0.52 in FY 2024). Revenue: CN¥10.5b (up 7.8% from FY 2024). Net income: CN¥540.7m (down 10% from FY 2024). Profit margin: 5.1% (down from 6.1% in FY 2024). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is expected to decline by 3.5% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in China are expected to grow by 13%. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Apr 08
Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 28, 2026 Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 28, 2026, at 13:00 China Standard Time. Location: No. 46, Waisha Road, Jiaojiang District, Taizhou, Zhejiang China Announcement • Mar 30
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Major Estimate Revision • Jan 13
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥9.74b to CN¥9.34b. EPS estimate also fell from CN¥0.41 per share to CN¥0.35 per share. Net income forecast to shrink 7.5% next year vs 28% growth forecast for Pharmaceuticals industry in China . Consensus price target up from CN¥7.00 to CN¥7.50. Share price rose 3.8% to CN¥10.59 over the past week. Price Target Changed • Jan 12
Price target increased by 12% to CN¥7.50 Up from CN¥6.70, the current price target is provided by 1 analyst. New target price is 29% below last closing price of CN¥10.54. Stock is up 37% over the past year. The company is forecast to post earnings per share of CN¥0.35 for next year compared to CN¥0.52 last year. Announcement • Dec 26
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 08, 2026 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 08, 2026 Announcement • Dec 19
Guangzhou Pharmaceutical Co., Ltd signed the equity transaction contract and the supplementary agreement of the equity transaction contract to acquire ZHEJIANG PHARMACEUTICAL INDUSTRY CORP.,LTD. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 500 million. Guangzhou Pharmaceutical Co., Ltd signed the equity transaction contract and the supplementary agreement of the equity transaction contract to acquire ZHEJIANG PHARMACEUTICAL INDUSTRY CORP.,LTD. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 500 million on December 17, 2025. A cash consideration of CNY 500.5 million will be paid by Guangzhou Pharmaceutical Co., Ltd. PHARMACEUTICAL INDUSTRY CORP., LTD.
For the period ending December 31, 2024, ZHEJIANG PHARMACEUTICAL INDUSTRY CORP.,LTD. reported total revenue of CNY 4.24 billion net income of CNY 29.88 million. As of December 31, 2024, ZHEJIANG PHARMACEUTICAL INDUSTRY CORP.,LTD. reported total assets of CNY 2.1 billion and total common equity of CNY 708.09 million. As of December 17, 2025 target board has approved this deal. The deal is conditional upon antitrust approval from chinese regulatory authorities and target shareholders approval.
Pan-China Certified Public Accountants LLP acted as accountant for Guangzhou Pharmaceutical Co., Ltd. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.14 (vs CN¥0.068 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.14 (up from CN¥0.068 in 3Q 2024). Revenue: CN¥2.67b (up 1.6% from 3Q 2024). Net income: CN¥161.9m (up 102% from 3Q 2024). Profit margin: 6.1% (up from 3.0% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has remained flat and the company’s share price has also remained flat. Announcement • Sep 30
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Price Target Changed • Jul 07
Price target increased by 11% to CN¥7.00 Up from CN¥6.30, the current price target is provided by 1 analyst. New target price is 35% below last closing price of CN¥10.75. Stock is up 55% over the past year. The company is forecast to post earnings per share of CN¥0.41 for next year compared to CN¥0.52 last year. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥10.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total loss to shareholders of 12% over the past three years. Announcement • Jun 30
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 New Risk • May 17
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 6.5% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • May 13
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 100 million worth of its shares. Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at a price not exceeding CNY 13 per share. The repurchases will be funded using the company's own funds. The shares repurchased will be used for employee stock ownership plans or equity incentives . The repurchase program will be valid for 12 months. Reported Earnings • Apr 01
Full year 2024 earnings: Revenues exceed analyst expectations Full year 2024 results: Revenue: CN¥9.79b (down 5.7% from FY 2023). Net income: CN¥601.2m (up CN¥694.4m from FY 2023). Profit margin: 6.1% (up from net loss in FY 2023). Revenue exceeded analyst estimates by 3.2%. Revenue is forecast to grow 1.9% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Announcement • Mar 29
Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 18, 2025 Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 18, 2025, at 13:00 China Standard Time. Location: No. 46, Waisha Road, Jiaojiang District, Taizhou, Zhejiang China Announcement • Mar 28
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Dec 27
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.031 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.068 (up from CN¥0.031 in 3Q 2023). Revenue: CN¥2.63b (flat on 3Q 2023). Net income: CN¥80.1m (up 113% from 3Q 2023). Profit margin: 3.0% (up from 1.4% in 3Q 2023). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Price Target Changed • Aug 21
Price target decreased by 10.0% to CN¥6.30 Down from CN¥7.00, the current price target is provided by 1 analyst. New target price is 15% below last closing price of CN¥7.39. Stock is down 27% over the past year. The company is forecast to post earnings per share of CN¥0.36 next year compared to a net loss per share of CN¥0.08 last year. Reported Earnings • Aug 20
Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.18 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.16 (down from CN¥0.18 in 2Q 2023). Revenue: CN¥2.52b (down 16% from 2Q 2023). Net income: CN¥186.7m (flat on 2Q 2023). Profit margin: 7.4% (up from 6.2% in 2Q 2023). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 20, 2024 Announcement • May 01
Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024 Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Taizhou, Zhejiang China Reported Earnings • Apr 30
Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022) Full year 2023 results: CN¥0.08 loss per share (down from CN¥0.42 profit in FY 2022). Revenue: CN¥10.4b (down 14% from FY 2022). Net loss: CN¥93.2m (down 119% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 18% per year. Announcement • Mar 29
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥7.39, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 51% over the past three years. Announcement • Dec 29
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024 Price Target Changed • Dec 22
Price target decreased by 13% to CN¥8.30 Down from CN¥9.50, the current price target is provided by 1 analyst. New target price is 8.5% below last closing price of CN¥9.07. Stock is down 16% over the past year. The company is forecast to post earnings per share of CN¥0.49 for next year compared to CN¥0.42 last year. New Risk • Nov 02
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 49% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.0% per year for the foreseeable future. Minor Risks High level of debt (49% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.031 (up from CN¥0.01 in 3Q 2022). Revenue: CN¥2.64b (down 12% from 3Q 2022). Net income: CN¥37.7m (up 212% from 3Q 2022). Profit margin: 1.4% (up from 0.4% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Oct 28, 2023 Reported Earnings • Aug 05
Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.15 in 2Q 2022). Revenue: CN¥3.00b (up 8.6% from 2Q 2022). Net income: CN¥187.1m (up 1.8% from 2Q 2022). Profit margin: 6.2% (down from 6.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Aug 22, 2023 Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021) Full year 2022 results: EPS: CN¥0.42. Revenue: CN¥12.0b (flat on FY 2021). Net income: CN¥489.0m (flat on FY 2021). Profit margin: 4.1% (up from 4.0% in FY 2021). Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Ren Hui Fu was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.01 (down from CN¥0.19 in 3Q 2021). Revenue: CN¥3.01b (down 3.1% from 3Q 2021). Net income: CN¥12.1m (down 95% from 3Q 2021). Profit margin: 0.4% (down from 7.1% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Sep 22
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares. Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces a share repurchase program. Under the program, the company will repurchase up to CNY 195 million worth of its shares. The shares will be repurchased at a price not exceeding CNY 13 per share. The repurchases will be funded using the company's own funds. The shares repurchased will be used for implementing the employee stock ownership plan. The repurchase program will be valid for 12 months. Announcement • Aug 24
Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million. Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million on August 19, 2022. The transaction is subject to approval of merger agreement by target board. The board approved the deal on August 19, 2022. Zhejiang Hisun Animal Health-care Products Co., Ltd reported total assets and net assets of CNY 61,772 million and CNY 14,502 million. Reported Earnings • Jul 20
Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.27 (up from CN¥0.13 in 2Q 2021). Revenue: CN¥2.76b (down 6.0% from 2Q 2021). Net income: CN¥183.8m (up 19% from 2Q 2021). Profit margin: 6.7% (up from 5.3% in 2Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • May 26
Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million. Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million on May 23, 2022. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥12.57, the stock trades at a trailing P/E ratio of 30.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 12% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ren Hui Fu was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020) Full year 2021 results: EPS: CN¥0.43. Revenue: CN¥12.1b (up 6.9% from FY 2020). Net income: CN¥486.9m (up 17% from FY 2020). Profit margin: 4.0% (up from 3.7% in FY 2020). The increase in margin was driven by higher revenue. Products in clinical trials Phase I: 4 Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥17.20, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥14.27, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥14.27, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥14.50, the stock trades at a trailing P/E ratio of 30.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 17% over the past three years. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.10b (up 9.4% from 3Q 2020). Net income: CN¥219.3m (up 115% from 3Q 2020). Profit margin: 7.1% (up from 3.6% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 01
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥2.94b (up 4.2% from 2Q 2020). Net income: CN¥154.4m (down 51% from 2Q 2020). Profit margin: 5.3% (down from 11% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.07b (up 23% from 1Q 2020). Net income: CN¥125.7m (up CN¥197.1m from 1Q 2020). Profit margin: 4.1% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 23
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥11.4b (up 2.6% from FY 2019). Net income: CN¥417.2m (up 348% from FY 2019). Profit margin: 3.7% (up from 0.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 04
New 90-day low: CN¥15.49 The company is down 4.0% from its price of CN¥16.06 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Announcement • Jan 22
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Mar 23, 2021 Is New 90 Day High Low • Dec 22
New 90-day high: CN¥18.41 The company is up 5.0% from its price of CN¥17.58 on 23 September 2020. The Chinese market is also up 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Announcement • Dec 18
CHIPSCREEN and HISUN Reach A Strategic Cooperation SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. announced that they have reached a strategic cooperation. CHIPSCREEN BIOSCIENCES BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right to promote Bilessglu (Chiglitazar Sodium tablets), independently developed and manufactured by its wholly-owned subsidiary CHENGDU CHIPCREEN PHARMACEUTICAL CO., LTD., in 19 provinces and regions in China. This cooperation intends to quickly provide to Chinese patients with this innovative diabetes treatment mechanism. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. Dr. Lu Xianping, Chairman of CHIPCREEN BIOSCIENCES, and Mr. Li Yan, President of HISUN PHARMACEUTICAL, signed a granting agreement, marking a milestone for the two parties to establish a long-term, stable and mutually beneficial strategic partnership. Is New 90 Day High Low • Nov 03
New 90-day low: CN¥15.63 The company is down 23% from its price of CN¥20.35 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 13% over the same period. Announcement • Sep 22
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion. Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion on July 6, 2020. According to the agreement between dated July 21, 2020, Zhejiang Hisun Pharmaceutical and seller, the estimated transaction price range of the target assets is tentatively set at CNY 4.3 billion to CNY 4.5 billion. The final transaction price shall be based on the assessment value determined in the asset assessment report issued by an asset assessment agency with securities and futures qualifications on June 30, 2020 as the assessment benchmark and filed by the corresponding state-owned assets supervision and administration department. The consideration will be paid as CNY 1.5 billion in cash, and 65% of the remaining transaction price (that is, the transaction consideration of the target asset minus the transaction consideration of CNY 1.5 billion that Zhejiang Hisun Pharmaceutical pays to the seller in cash) will be paid by Zhejiang Hisun Pharmaceutical by issuing shares, and 35% of the remaining transaction price will be paid by Zhejiang Hisun Pharmaceutical by issuing convertible corporate bonds. As on August 31, 2020, Zhejiang Hisun Pharmaceutical Co., Ltd. will pay CNY 1.5 billion by cash, CNY 1.88 billion by the issue of shares and CNY 1.02 billion by issuing convertible corporate bonds. Upon completion, HPPC Holding SARL will hold 143 million shares and 10 million convertible corporate bond. The shares of Zhejiang Hisun Pharmaceutical acquired by the seller through this exchange shall not be transferred in any way during 12 months from the date of the end of the share issuance. As of September 21, 2020, The shareholders of Zhejiang Hisun Pharmaceutical Co., Ltd. approved the issuance of shares, convertible corporate bonds and payment of cash to purchase HanHui Pharmaceuticals Co., Ltd. The transaction has been approved by the Board and the shareholders of Zhejiang Hisun Pharmaceutical Co., Ltd. The transaction is approved by CSRC. Announcement • Jul 10
Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announced a private placement on July 7, 2020. Announcement • Jul 08
Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020 Zhejiang Hisun Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020 
